This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer: This Froth Has to Be Reined In

NEW YORK ( Real Money) -- You can't stop the froth, even in the midst of a new Cold War between Russia and the West. You can't stop it even as major stocks seem to be rolling over left and right. You can't stop it even when the established stocks in a group are getting crushed but initial public offerings in the same sector come along and roar.

Take last Friday. Castlight Health (CSLT) came public to tremendous fanfare, soaring 140% the first day. Why? Because this is a company that offers a software-as-a-service cloud-based solution for health care benefits. Whoop-de-do. Have you seen how badly (CRM), Workday (WDAY), Veeva (VEEV) and Concur Technologies (CNQR) shares have been trading after excellent quarters? These companies are the cream of the crop, and they have been fabulous shorts for two weeks now -- and we like Castlight?

I suspect this week will be more of the same when several other names come public: Paylocity, a cloud-based payroll-and-human-capital company; Q2 Holdings, a cloud-based community­-banking play; Amber Road, a global trade cloud-based company; and Globoforce, a cloud-based social-recognition software business. (Ticker symbols will be "PTCY," "QTWO," "AMBR" and "THNX," respectively).

These are all versions of what could easily be described as existing companies. In fact, Paylocity sounds like Workday-meets-Cornerstone OnDemand (CSOD). As for Q2 Holdings, has a community-banking initiative -- check its site. Cloud-based social recognition and global trade businesses? I am sure Globoforce and Amber Road have something proprietary, but I have to ask: "Do you really need to come public now?" What's the darned hurry? The answer, of course, is that the public market is divorced right now from the soon-to-be public IPOs, and that is always a bad sign.

Must Read: Ukraine Situation; Bonds; Market Weakness: Best of Kass

It's the same thing with biotech. Upcoming IPOs for Akebia Therapeutics, an antianemia therapy company and for Versartis, a growth-hormone play, presumably will dazzle (under respective tickers "AKBA" and "VSAR") -- even as Celgene (CELG), Gilead (GILD), Isis (ISIS), Jazz (JAZZ) and Seattle Genetics (SGEN) are becoming unglued.

Now, I happen to like the incumbents. I am not making a judgment about those. I think the incumbents that I have mentioned here in the cloud and biotech spaces will come back. Many are fine companies.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs